AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From AP Worldstream)
Byline: ANITA SNOW
Syneron Medical Ltd. stock fell Tuesday after the U.S. Food and Drug Administration delayed approval of the medical device maker's cellulite product.
Shares of the Israeli company traded midday Tuesday at $30.33, down $6.87, or 18 percent, on the Nasdaq Stock Market.
Analysts see the delay pushing back U.S. approval for VelaSmooth, a device used to treat cellulite, by six months to one year, and hurting U.S. sales by about $5 million (A3.8 million).
Late Monday, the FDA asked the Israeli medical device maker to resubmit clinical data for VelaSmooth under a premarketing approval…